ProShares Ultra NASDAQ Biotechnology
23 hedge funds and large institutions have $4.04M invested in ProShares Ultra NASDAQ Biotechnology in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Holders
23
Holding in Top 10
–
Calls
$332K
Puts
$164K
Top Buyers
| 1 | +$1.08M | |
| 2 | +$240K | |
| 3 | +$78.9K | |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$48.2K |
| 5 |
GC
Garde Capital
Seattle,
Washington
|
+$11.4K |
Top Sellers
| 1 | -$228K | |
| 2 | -$203K | |
| 3 | -$146K | |
| 4 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$145K |
| 5 |
CWM
Crowley Wealth Management
Wilmington,
Delaware
|
-$50.7K |